论文部分内容阅读
胰腺癌作为目前最致命的人类肿瘤类型，其生物学上的侵袭性、早期发现策略的空白和有效治疗手段的缺乏是导致胰腺癌生存率低的主要原因。深入了解胰腺癌的发生发展机制，早期诊断胰腺癌，有效预测胰腺癌的复发及预后，探索关键的治疗靶点是新时代胰腺癌研究的重中之重。大规模的基因组研究对了解胰腺癌关键驱动基因奠定了一定的基础。在后基因组时代，通过对胰腺癌患者的肿瘤组织和体液进行蛋白测序，将逐渐开创一个精准诊治胰腺癌的新时代。目前全球范围以胰腺外科为主的胰腺癌多学科诊疗(MDT)医疗团队利用癌症基因组图谱(TCGA)、高通量基因表达数据库(GEO)、国际癌症基因组联盟(ICGC)等大规模公开数据库，结合各中心小规模测序数据，逐渐揭开胰腺癌在不同生物过程中的核心肿瘤标志物，进而为临床转化治疗提供理论基础及指导。“,”As the most deadly human tumor, pancreatic cancer has a low survival rate due to its biological invasiveness, lack of early detection strategies, and short of effective treatment. The research of pancreatic cancer in the new era focuses on understanding pancreatic cancer′s pathogenesis, early diagnosis, effective prediction of its recurrence and prognosis, and exploration of critical therapeutic targets. Moreover, large-scale genomic studies have laid a foundation for understanding essential driver genes in pancreatic cancer. In the post-genomic era, protein sequencing in tumor tissues and body fluids of pancreatic cancer patients will gradually open up a new period of accurate diagnosis and treatment of pancreatic cancer. The global multidisciplinary team of pancreatic cancer diagnosis and treatment will utilize large-scale open databases and small-scale sequencing data of each center to gradually uncover the core tumor markers of pancreatic cancer in different biological processes, provide theoretical basis and guidance for clinical translational therapy.